European Innovation Council

ATXA Therapeutics Limited is a pharmaceutical company based in Dublin, Ireland, focused on developing novel small molecule drugs for the treatment of pulmonary arterial hypertension (PAH). Established in 2015 as a spin-out from University College Dublin, the company has leveraged over 20 years of research and more than €15 million in grant funding to advance its clinical trials and secure marketing authorization for its therapies. ATXA's innovative approach involves targeting human thromboxane receptors to enhance vasodilation and reduce vasoconstriction, addressing significant unmet medical needs in PAH and other cardiovascular conditions. The team comprises experts in various fields, including cardiovascular and cancer biology, drug discovery, and preclinical pharmacokinetics, positioning ATXA to develop more effective treatments than current standard care options. The company aims to improve treatment outcomes for patients suffering from PAH and related conditions through its advanced therapies.

AMT Medical BV has developed a minimal invasive medical device for heart bypass surgery. The AMT Heart Bypass System is based on the ELANA bypass, technology invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team of the UMCU. The technique is designed to make the traditional heart bypass procedures faster, safer, easier and less invasive for the patient.The product has been fully developed, production process has been designed, all pre-clinical trials have finished, a clinical multi-center trial will commence late 2019, early 2020.

Developer of computing software intended to speed up the process of physical verification of integrated circuits (ICs). The company researches and creates technologies and software that integrate advanced parallel computing, accelerate machine simulations, and automate circuit verification, enabling clients to ramp up their IC design and verification process, deliver custom IP, and ensure bug-free silicon.

Xelera's software makes state-of-the-art accelerator technology accessible to commercial applications in the data center and in the cloud. Due to the growing data volume and emerging demand for real-time analytics, businesses are increasingly required to build up accelerated data processing capabilities. FPGAs and GPUs will become an integral part of tomorrow’s data centers, cloud services and IoT infrastructure, powering a broad range of constantly evolving business applications. Accelerator technology can provide orders-of-magnitude acceleration to business-critical applications using Big Data analytics, machine learning, database management and to IoT infrastructures. FPGAs boost the energy efficiency of data center servers and can substantially reduce TCO.

Artiria Medical SA develops micro-actuated device to treat vascular diseases. Its products bring micromotion deep in the brain arteries, enabling a navigation and stroke treatment. It empowers catheters and guidewires. Artiria Medical SA was incorporated in 2019 and is based in Lausanne, Switzerland.

Pasqal SAS, founded in 2019 and headquartered in Paris, France, specializes in the manufacture of quantum information processors utilizing atomic arrays. The company focuses on developing full-stack quantum computing technology that simulates complex phenomena to facilitate scientific discovery. Its innovative approach employs qubits made of neutral atoms organized in large two-dimensional and three-dimensional arrays, which enables analog computing. This technology addresses a variety of challenges, including optimization, drug discovery, and machine learning, empowering organizations to tackle complex problems across these fields.

Pasqal SAS, founded in 2019 and headquartered in Paris, France, specializes in the manufacture of quantum information processors utilizing atomic arrays. The company focuses on developing full-stack quantum computing technology that simulates complex phenomena to facilitate scientific discovery. Its innovative approach employs qubits made of neutral atoms organized in large two-dimensional and three-dimensional arrays, which enables analog computing. This technology addresses a variety of challenges, including optimization, drug discovery, and machine learning, empowering organizations to tackle complex problems across these fields.

Equal1 Laboratories is accelerating the introduction of useful, cost effective quantum computers within a three-year time horizon. The company has developed a disruptive, scalable and cost-effective quantum computing technology, based on a commercially available silicon semiconductor process. Our solution uses nanometer-scale quantum dots to form qubits on a standard silicon CMOS process. Along with silicon qubits, we have integrated all functions required for a quantum processing unit (QPU) – the brain of the quantum computer – which operates at 3 kelvin with over 10 million transistors. This is the first integrated quantum processing unit of its kind.

Equal1 Laboratories is accelerating the introduction of useful, cost effective quantum computers within a three-year time horizon. The company has developed a disruptive, scalable and cost-effective quantum computing technology, based on a commercially available silicon semiconductor process. Our solution uses nanometer-scale quantum dots to form qubits on a standard silicon CMOS process. Along with silicon qubits, we have integrated all functions required for a quantum processing unit (QPU) – the brain of the quantum computer – which operates at 3 kelvin with over 10 million transistors. This is the first integrated quantum processing unit of its kind.

SiPearl is a semiconductor company that commercializes the work of the European Processor Initiative (EPI) and bring a low-power microprocessor to market for exascale supercomputing. The company aims to design, market, and distribute its first range of processors with a commercial launch in 2022 based on a roadmap closely aligned with the European Union’s goals. It has already committed to producing its chips using N6 or better processes from TSMC. It was founded in 2019 and headquartered in Maisons-Laffitte, Île-de-France.

Pasqal SAS, founded in 2019 and headquartered in Paris, France, specializes in the manufacture of quantum information processors utilizing atomic arrays. The company focuses on developing full-stack quantum computing technology that simulates complex phenomena to facilitate scientific discovery. Its innovative approach employs qubits made of neutral atoms organized in large two-dimensional and three-dimensional arrays, which enables analog computing. This technology addresses a variety of challenges, including optimization, drug discovery, and machine learning, empowering organizations to tackle complex problems across these fields.

Developer of batteryless microcontrollers intended to convert one IoT device at a time to a battery-free ecosystem. The company's wireless microcontrollers are self-powered and battery-free which harvest energy from their surroundings making health information more accessible and easier to interpret by reducing the barrier between people and healthcare technology, enabling individuals to be more confident about their health and spend more time focusing on everything else.